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Aims The incidence and predictors of stroke in patients with heart failure and preserved ejection fraction (HF-PEF), but
without atrial fibrillation (AF), are unknown. We described the incidence of stroke in HF-PEF patients with and
without AF and predictors of stroke in those without AF.
...................................................................................................................................................................................................
Methods
and results
We pooled data from the CHARM-Preserved and I-Preserve trials. Using Cox regression, we derived a model for
stroke in patients without AF in this cohort and compared its performance with a published model in heart failure
patients with reduced ejection fraction (HF-REF)—predictive variables: age, body mass index, New York Heart
Association class, history of stroke, and insulin-treated diabetes. The two stroke models were compared and Kaplan–
Meier curves for stroke estimated. The risk model was validated in a third HF-PEF trial. Of the 6701 patients, 4676 did
not have AF. Stroke occurred in 124 (6.1%) with AF and in 171 (3.7%) without AF (rates 1.80 and 1.00 per 100
patient-years, respectively). There was no difference in performance of the stroke model derived in the HF-PEF
cohort and the published HF-REF model (c-index 0.71, 95% confidence interval 0.57–0.84 vs. 0.73, 0.59–0.85, respec-
tively) as the predictive variables overlapped. The model performed well in the validation cohort (0.86, 0.62–0.99).
The rate of stroke in patients in the upper third of risk approximated to that in patients with AF (1.60 and 1.80 per
100 patient-years, respectively).
...................................................................................................................................................................................................
Conclusions A small number of clinical variables identify a subset of patients with HF-PEF, but without AF, at elevated risk of
stroke.
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Introduction
Up to half of patients with heart failure have a preserved ejection
fraction (HF-PEF).1–3 These patients differ from heart failure patients
with reduced ejection fraction (HF-REF) in several aspects—they
tend to be older, are more often women, and are more likely to have
a history of hypertension and atrial fibrillation (AF); they are less likely
to have coronary artery disease. Although, mortality rates may not
be as high as in patients with HF-REF, the prognosis of HF-PEF
patients is considerably worse than that of patients with hyperten-
sion, angina pectoris, AF, or diabetes in the same age range and gen-
der distribution.4 The single most common cause of hospital
admission in these patients is worsening heart failure and this, along
with death, has been the focus of therapeutic interventions in HF-
PEF.4 However, given the demographic profile and co-morbidity clus-
ter characterizing these patients, stroke may also be a clinically
important outcome in HF-PEF. Little is known about the incidence of
stroke in HF-PEF, particularly in the absence of AF.
To investigate this further, we therefore combined and analysed
patient-level data from two large HF-PEF trials, the Candesartan in
Heart failure Assessment of Reduction in Mortality and Morbidity-
Preserved trial (CHARM-Preserved, ClinicalTrials.gov NCT0
0634712)5 and the Irbesartan in Heart Failure with Preserved Systolic
Function trial (I-Preserve, NCT00095238),6 to provide a robust esti-
mate of the current incidence of stroke in patients with HF-PEF, with
and without AF. We also tested a simple clinical model, developed in
HF-REF,7 for predicting the risk of stroke in patients without AF in this
pooled dataset. Easy identification of those at highest risk of stroke
coupled with the availability of new oral anticoagulants with a low risk
of bleeding might allow for a stroke prevention strategy which has an
acceptable benefit/risk balance in patients with HF without AF.
Methods
Trial patients
In order to have a sufficiently large number of HF-PEF patients with-
out AF for analysis, we pooled data from the CHARM-Preserved
(NCT00634712) and I-Preserve (NCT00095238) trials. Each was a
randomized, double-blind, placebo-controlled, multicentre trial and
was approved by the appropriate institutional review boards.
CHARM-Preserved and I-Preserve enrolled 3023 and 4128 patients,
respectively.5,6 Together, these trials included a broad spectrum of
patients with chronic HF-PEF.
CHARM-Preserved enrolled patients aged 18 years in New
York Heart Association (NYHA) functional class II–IV with a left ven-
tricular ejection fraction (LVEF)>40% (although for the purposes of
this study we included only patients with an LVEF 45%). I-Preserve
enrolled patients aged60 years in NYHA functional class II–IV with
an LVEF45% and corroborating ECG, echocardiographic or radio-
logic evidence. In addition, patients must have been hospitalized for
heart failure in the preceding 6 months or, if not, had to be in NYHA
functional class III or IV. N-terminal pro B-type natriuretic peptide
(NT-proBNP) was measured at baseline in I-Preserve but not in
CHARM-Preserved. In CHARM-Preserved, patients were randomly
assigned to candesartan (target dose of 32 mg once daily) or match-
ing placebo.5 In I-Preserve, patients were randomized to irbesartan
(target dose 300 mg once daily) or matching placebo.6 The primary
outcome in CHARM-Preserved was the composite of cardiovascular
death or HF hospitalization5,8 and in I-Preserve it was the composite
of all-cause mortality or cardiovascular hospitalization.6,9 The median
follow-up in CHARM-Preserved was 3.1 years and in I-Preserve it
was 4.1 years. Study treatment did not reduce the risk of the primary
outcome or the risk of stroke in the either trial.5,6
Incident stroke
Incident strokes were centrally adjudicated by an independent end-
point committee in each trial using similar definitions and stroke was
part of the primary or secondary composite cardiovascular out-
comes in both trials.5,6,8,9 Stroke in both trials was defined as a persis-
tent (24 h) disturbance of focal neurological function resulting in
symptoms thought to be due to cerebral infarction, evidence of hae-
morrhage or for which there is no certain aetiology.5,6,8,9
Incident atrial fibrillation
The occurrence of AF was retrospectively collected in CHARM-
Preserved during the trial close-out using a specifically designed case-
report form. Incident AF was recorded prospectively in I-Preserve,
using a specific case-report form.
Statistical methods
We included only patients with an LVEF of45% (all 4128 patients in
I-Preserve and 2573 of the 3023 in CHARM-Preserved). Patients
with AF were defined as those with either AF confirmed on their
baseline ECG or a history of AF. The remaining patients were defined
as those ‘without AF’. Descriptive statistics were used to describe
the pooled patient population from both trials and to compare these
two subgroups, using means (standard deviation) or medians [inter-
quartile range (IQR)] for continuous variables and count (percent-
age) for categorical variables.
The incidence rate of stroke (per 100 patient-years) was calculated
over the trial follow-up period and was compared among the AF and
no AF subgroups. We plotted Kaplan–Meier (KM) curves for the
occurrence of stroke, according to AF status. To satisfy the assump-
tion of the independence of stroke events, recurrent stroke events in
a patient after randomization were not included in the analysis.
Continuous variables [e.g. body mass index (BMI), ejection frac-
tion, and creatinine level] were assessed by visual inspection of
restricted cubic splines to identify potential non-linear effects. Uni-
and multivariable predictors of the risk for stroke were evaluated
using Cox proportional hazards regression analysis in patients with-
out AF. Two separate multivariable analyses for stroke were created.
First, an ‘HF-PEF stroke model’ was created using established predic-
tors of ischaemic stroke10–15 with the addition of variables that were
significant (P< 0.05) in univariable analysis of our dataset. The final
list of variables included was age, sex, LVEF, NYHA class III/IV, BMI,
creatinine level, systolic blood pressure, history of stroke, hyperten-
sion, and diabetes treated with insulin. Second, we applied a recently
published multivariable predictive model for stroke in patients with
HF-REF (HF-REF stroke model) in our HF-PEF cohort.7 The five vari-
ables included in this model were age, BMI, NYHA class, history of
stroke, and diabetes treated with insulin. There were no data missing
for the baseline variables used either model. We calculated the haz-
ard ratio and corresponding 95% confidence intervals (95% CI) to
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express the hazard rate of stroke. The statistical contribution of each
variable to the predicted risk of stroke was assessed by the v2 statis-
tic. In order to be consistent with our previous publication,7 we com-
pared each model’s discrimination ability using estimates of overall
c-index for the Cox regression models according to the method of
Pencina and D’Agostino,16 as outlined by Liu et al.17 We pre-
determined that we would proceed using only the HF-REF stroke
model if the overall c-indexes for the two models were not meaning-
fully different.
The coefficients from statistically significant variables in the final
multivariable model were used to calculate an individual patient’s risk
score for stroke. The KM curves for occurrence of stroke according
to tertiles of risk score were plotted.
Final model calibration and the ability to separate patients into risk
groups were assessed by observing predicted compared with
observed outcomes in terciles, and by using the Hosmer–Lemeshow
goodness-of-fit test. The model’s discrimination abilities were eval-
uated by the overall c-index.16,17
We also conducted a sensitivity analysis to compare the cumula-
tive incidence function for stroke estimated using competing risk
technique (to account for the competing risk of death)19,20 with the
rates of stroke described from the traditional KM curves above. We
also compared the overall c-index of the model with the traditional
Harrell’s c-statistic.16–18
Finally, we validated the preferred risk model in a third HF-PEF
trial: the Treatment of Preserved Cardiac Function Heart Failure
with an Aldosterone Antagonist (TOPCAT) (NCT00094302).21
TOPCAT included patients aged50 years with at least one symp-
tom and sign of heart failure, an LVEF45% and either a hospitaliza-
tion with heart failure in the preceding 12 months or an elevated
NT-proBNP or BNP.
All analyses were undertaken using SAS version 9.3 (SAS Institute,
Inc., Cary, NC, USA).
Results
Of the 6701 patients with an LVEF45%, 2025 (30%) had a history
of AF or AF on their baseline ECG and 4676 patients (70%) had no
AF.
Baseline characteristics
The baseline characteristics of patients with and without AF are
shown in the Supplementary material online, Table S1. The baseline
characteristics of patients without AF, according whether or not they
experienced a subsequent stroke, are shown in Table 1.
Patients with and without atrial fibrillation
Patients without AF were younger and were more likely to have a his-
tory of coronary artery disease and hypertension, compared with
patients with AF. Patients without AF also had a slightly higher systolic
blood pressure but had a lower mean serum creatinine and much
lower median NT-proBNP level than patients with AF. There were
also notable differences in medical therapy, particularly in use of anti-
platelet therapy (69% of patients without AF vs. 39% of those with
AF) and anticoagulant treatment (6% vs. 57%, respectively), but also
in relation to diuretics, mineralocorticoid receptor antagonists, anti-
arrhythmic agents, and digoxin.
Patients without atrial fibrillation—with and without
incident stroke during follow-up
Among patients without AF, those who experienced a stroke (com-
pared with those who did not) were older, more likely to have a his-
tory of diabetes, hypertension, and stroke and had worse NYHA
functional class. Patients experiencing stroke also had a higher systolic
blood pressure, creatinine, and NT-proBNP level. Compared with
those not experiencing stroke, those who did were less likely to be
treated with lipid lowering therapy but more likely to be taking
nitrates, anti-platelet therapy, and insulin. Very few patients in either
group were treated with an oral anticoagulant (263 in total, 6%).
LVEF did not differ between patients with and without stroke.
Rates of stroke
Patients with atrial fibrillation
The median follow-up time in patients with AF was 3.4 (IQR: 2.8–4.4)
years and 124 of these 2025 patients (6.1%) experienced a stroke
(1.80 per 100 patient-years). The 1, 2, and 3 year KM rates for stroke
were 1.5 (95% CI: 1.0–2.1)%, 3.5 (95% CI: 2.7–4.4)%, and 5.5 (95% CI:
4.5–6.6)%, respectively (Figure 1). The stroke rate in patients treated
with an anticoagulant was 1.51 per 100 patient-years; and in those not
treated with an anticoagulant it was 2.19 per 100 patient-years (yearly
rates shown in the Supplementary material online, Figure S1).
Patients without atrial fibrillation
The median follow-up time in patients without AF was 3.5 (IQR: 3.0–
4.6) years and 171 of these 4676 patients (3.7%) experienced a
stroke (1.00 per 100 patient-years). The 1, 2, and 3 year KM rates of
stroke were 1.0 (95% CI: 0.8–1.4)%, 2.0 (95% CI: 1.7–2.5)%, and 3.0
(95% CI: 2.5–3.5)%, respectively (Figure 1).
Incident AF and risk of stroke
In CHARM-Preserved, 1781 patients did not have AF at baseline.
Out of 1781, 59 patients (3.3%) experienced a stroke. Of these 59
patients, 10 (17%) developed new AF before the occurrence of their
stroke; the number of patients with a stroke without preceding AF
was 49 (83%). Development of AF reported was not reported in any
patient following a stroke.
In I-Preserve, 2895 patients did not have AF at baseline. Out of
2895, 112 patients (4%) experienced a stroke. Of these 112 patients,
18 (16%) developed new AF before the occurrence of their stroke;
the number of patients with a stroke without preceding AF was 94
(84%). Twenty patients (18%) with an incident stroke had new AF
reported before or after their stroke.
Predictors of stroke in patients with
heart failure and preserved ejection
fraction without AF
Figure 2 and Supplementary material online, Table S2 show the rela-
tionship between baseline variables and risk of stroke (univariable
analysis). Supplementary material online, Table S3 shows an adjusted
analysis using the four independent predictors identified in a multi-
variable stroke model developed in the present HF-PEF cohort
744 A.H. Abdul-Rahim et al.
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Table 1 Baseline characteristics according to stroke outcome in patients without AF
Patients without AF (N54676) Non-stroke (n54505) Stroke (n5171)
Demographics, n (%)
Age, year 696 9 696 9 716 8
<65 1400 (30) 1366 (30) 34 (20)
65 to< 75 2032 (43) 1956 (43) 76 (44)
75 1244 (27) 1183 (26) 61 (36)
Race
Caucasians 4273 (91) 4116 (91) 157 (92)
Afro-American/Afro-Caribbean 155 (3) 148 (30) 4 (7)
Other 248 (5) 241 (5) 7 (4)
Female sex 2542 (54) 2459 (55) 83 (49)
NYHA class
II 1657 (35) 1612 (36) 42 (26)
III 2918 (62) 2799 (62) 119 (70)
IV 101 (2) 94 (2) 7 (4)
Duration of heart failure, year
<2 2778 (59) 2673 (59) 105 (61)
2–5 1110 (24) 1076 (24) 34 (20)
>5 764 (16) 734 (16) 30 (18)
LV ejection fraction, % 586 9 586 9 576 8
Baseline vital signs
BMI, kg/m2 306 6 306 6 296 5
BP, mmHg
Systolic 1376 16 1376 16 1406 15
Diastolic 796 10 796 10 796 9
Pulse pressure 586 14 586 14 616 14
Heart rate, b.p.m. 716 11 716 11 716 10
Laboratory measurements
Serum creatinine, mmol/L 886 29 886 29 966 33
Haemoglobin, g/dL 146 2 146 2 146 1
NT-proBNPa, pg/mL(median6 IQR) 230 (104–537) 225 (104–525) 426 (170–1121)
Medical history, n (%)
Coronary heart disease 2960 (63) 2855 (63) 105 (61)
Myocardial infarction 1599 (34) 1534 (34) 65 (38)
Angina pectoris 2517 (54) 2429 (54) 88 (51)
CABG or PCI 1078 (23) 1044 (23) 34 (20)
Hypertension 3779 (81) 3632 (81) 147 (86)
Diabetes mellitus 1313 (28) 1245 (28) 68 (40)
Stroke 379 (8) 343 (8) 36 (21)
ICD 11 (0.2) 11 (0.2) 0 (0)
Current smoker 2597 (56) 2502 (56) 95 (56)
Medication, n (%)
Diuretic (loop or thiazide) 3392 (73) 3266 (73) 126 (74)
Loop diuretic 2278 (49) 2195 (49) 83 (49)
Thiazide diuretic 1481 (32) 1430 (32) 51 (30)
ACE inhibitor 1020 (22) 982 (22) 38 (22)
Aldosterone antagonist 788 (17) 753 (17) 35 (20)
Beta-blocker 2761 (59) 2663 (59) 98 (57)
Digitalis glycoside 405 (9) 391 (9) 14 (8)
Calcium channel blocker 1809 (39) 1747 (39) 62 (36)
Antiarrhythmic drug 179 (4) 173 (4) 6 (4)
Long-acting nitrate 1476 (32) 1410 (31) 66 (39)
Lipid lowering therapy 1786 (38) 1734 (38) 52 (30)
Continued
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(previous stroke, age, diabetes treated with insulin, and male sex).
These overlapped with the five independent predictors in the HF-REF
stroke model (previous stroke, age, diabetes treated with insulin,
BMI, and NYHA class) (Table 2). The overall c-index for the HF-PEF
model was 0.71 (95% CI: 0.57–0.84) compared with 0.73 (0.59–0.85)
using the HF-REF model (P-value for difference¼ 0.415). Thus, we
proceeded using the previously validated HF-REF model. This model
can be used to calculate an individual’s risk of stroke as described in
the Supplementary material online, Supplementary material.
Figure 3 shows the distribution of the risk score for stroke and illus-
trates the risk of stroke for a given score. A score of approximately
12 predicts a risk of stroke similar to that which was seen among
patients with AF in the current cohort. Figure 4 shows KM curves for
stroke with patients classified into three equal-sized groups according
to risk score. The number of strokes in tertiles 1, 2 and 3 were 37, 45
and 89, respectively. The 1, 2 and 3 year KM rates of stroke in the
two higher risk tertiles were tertile 2: 1.1 (95% CI: 0.7–1.7)%, 1.6
(95% CI: 1.1–2.4)%, and 2.4 (95% CI: 1.7–3.3)%, respectively; and ter-
tile 3: 1.4 (95% CI: 1.0–2.2)%, 3.2 (95% CI: 2.4–4.2)%, and 4.9 (95%
CI: 3.9–6.2)%, respectively (Figure 4). Patients in risk-tertile 3 had an
overall stroke rate of 1.60 per 100 patient-years.
Figure 5 shows the model’s goodness-of-fit by comparing observed
and expected probabilities of stroke at 3 years with the patients div-
ided into tertiles. The calibration was also assessed using the
Hosmer–Lemeshow test, which was P¼ 0.761.
Validation of stroke risk model
We tested the predictive model in TOPCAT, which included 1240
patients with and 2205 patients without AF. The mean follow-up was
3.5 years. There were 65 strokes in the patients with AF and 52
strokes in those without AF, giving stroke rates in patients with and
without AF 1.64 and 0.71 per 100 patients-years, respectively.
Using the same analytical approach (see Supplementary material
online, Table S4, Figures S2 and S3), the 1, 2 and 3 year KM rates of
stroke in patients without AF, in the two higher risk tertiles were: ter-
tile 2: 1.3 (95% CI: 0.6–2.4)%, 1.3 (95% CI: 0.6–2.3)% and 1.7 (95% CI:
0.9–2.9)%, respectively; and tertile 3: 1.5 (95% CI: 0.8–2.7)%, 1.7
(95% CI: 0.9–2.9)% and 2.6 (95% CI: 1.6–4.1)%, respectively. Patients
in risk-tertile 3 of the validation model derived from TOPCAT
cohort had an overall stroke rate of 1.06 per 100 patient-years. The
overall c-index for the model was 0.86 (95% CI: 0.62–0.99).
Sensitivity analysis that evaluated the cumulative incidence func-
tions of stroke for the corresponding KM curves reported above is
available in the Supplementary material online, Figures S4–S7. There is
little difference between the two types of curves. The comparison
for the ‘stroke in HF-REF’ model’s discrimination ability within the
....................................................................................................................................................................................................................
Table 1 Continued
Patients without AF (N54676) Non-stroke (n54505) Stroke (n5171)
Antiplatelet therapy 3204 (69) 3080 (68) 124 (73)
Anticoagulant therapy 263 (6) 255 (6) 8 (5)
Any antihthrombotic (antiplatelet or anticoagulant therapy) 3408 (73) 3278 (73) 130 (76)
Antidiabetic therapy 1096 (23) 1040 (23) 56 (33)
Insulin therapy 438 (9) 409 (9) 29 (17)
Placebo arm in the original trial 2322 (50) 2231 (50) 91 (53)
All continuous values are given in mean6 standard deviation unless stated otherwise.
AF, atrial fibrillation; n (%), number of observations (percentage of observations within the group); BMI, body mass index; BP, blood pressure; NYHA, New York Heart
Association; NT-proBNP, N-terminal pro B-type natriuretic peptide; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; ICD, implantable cardi-
overter defibrillator; ACE, angiotensin converting enzyme.
aAvailable in 2452 patients.
.................................................................................................
Table 2 List of variables from the ‘HF-REF model for
stroke’
Variables Coefficients from
HF-REF stroke model7
Previous Stroke 0.591
Diabetes treated with insulin 0.626
Age (per 10 years increase) 0.331
BMI (per 5 kg/m2 increase up to 30) 0.301
NYHA class (NYHA III and IV) 0.472
See the Supplementary material for explanation of how to use coefficients of the
variables to calculate individual patient’s risk score of stroke.
HF-REF, heart failure with reduced ejection fraction; BMI, body mass index;
NYHA, New York Heart Association.
Figure 1 Kaplan–Meier plot stroke for chronic heart failure
patients with preserved ejection fraction according to atrial fibrilla-
tion status at baseline. AF, atrial fibrillation.
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HF-PEF cohort using the overall c-index and the traditional Harrell’s
c-method is available in the Supplementary material online, Table S5.
Discussion
In this analysis, HF-PEF patients with AF were at a high risk of stroke,
with an average incidence rate of 1.8% per year which is similar to
that recently reported in HF-REF patients with AF (1.6% per year).7
HF-PEF patients without AF in this study had a lower risk of stroke
compared with those with AF. However, the overall rate of stroke in
HF-PEF patients without AF (1.0% per year) was similar to the rate we
recently reported in HF-REF patients without AF (1.2% per year).
Moreover, as in HF-REF, a small number of demographic and clinical
variables identified a subset of HF-PEF patients without AF who were
at greater risk of stroke than the remainder. Specifically, in our pooled
analysis, patients in the upper third of the risk score had a rate of stroke
(1.6% per year) which was higher than in HF-PEF patients with AF
receiving an anticoagulant (1.5% per year), although not as high as in
similar patients not treated with an anticoagulant (2.2% per year).
We have been unable to find other reports of the risk of stroke in
HF-PEF patients without AF although in patients in the same age range
in clinical trials for hypertension (i.e. with a similar co-morbid pheno-
type to HF-PEF) have a stroke risk of around 1% per year or less.22–26
In HF-PEF patients with AF randomized to warfarin in ARISTOTLE27
the rate of stroke was 1.4% per year which was similar to the rate in
anticoagulant-treated AF patients in our study (1.5% per year). In AF
patients with HF and an LVEF>40% in RELY-AF28 the rate of stroke
or systemic embolism was 2.07% per year in the warfarin group; in
ROCKET-AF29 the rate of the same outcome in similarly defined
patients was 2.06% per year. The higher event rates in the latter two
trials are due to broader composite outcome (which included non-
cerebral systemic embolism) and the requirement for patients in
these trials to have additional risk factors for stroke.
Figure 2 The relationship between baseline variables and risk of stroke in patients with heart failure and preserved ejection fraction without atrial
fibrillation. Variables are divided by quintiles. BMI, body mass index; BP, blood pressure; LV, left ventricular; NT-proBNP, N-terminal pro-B-type
natrieretic peptide.
Stroke in HF-PEF 747
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The similar risk of stroke in patients with HF-PEF and HF-REF, with-
out AF, is also of interest. We previously reported that LVEF was not
predictive of stroke in HF-REF patients without AF. Neither was
LVEF an independent predictor of stroke risk in this study although
we examined only patients with an LVEF45%. This finding is consis-
tent with observations in three recent trials comparing non-Vitamin
K antagonist oral anticoagulants with warfarin in patients with AF. In
those trials, the risk of stroke and systemic embolism was similar,
irrespective of LVEF category, in patients with AF and concomitant
HF. A similar conclusion was reached by the Atrial Fibrillation
Clopidogrel Trial with Irbesartan for Prevention of Vascular Events
(ACTIVE) in AF patients not treated with an oral anticoagulant where
the risk of stroke was similar in patients with concomitant HF-REF or
HF-PEF.30
As in HF-REF, we found that neither systolic blood pressure nor
history of hypertension was independent predictor of stroke.
Although this contrasts with the findings in other patient cohorts, it is
consistent with the ‘reverse epidemiology’ of heart failure and the
known association between higher blood pressure and better out-
comes in this condition.31–33 Likewise, we saw an association
between lower BMI and higher risk of stroke, another feature of the
‘reverse epidemiology’ in heart failure.31–33
A particular strength of this study is the validation of our predictive
model in another dataset (TOPCAT). Consequently, our findings
have clear clinical implications. With a small number of routinely col-
lected clinical variables it is possible to identify patients with HF-PEF,
but without AF, who may be at sufficiently high risk of stroke poten-
tially to justify anticoagulation. Clearly, there is as yet no trial evidence
to justify such treatment but our findings suggest a means of identifying
patients for such a trial. Consistent with this hypothesis, prior trials in
patients with heart failure and reduced ejection fraction collectively
suggest that anticoagulation can reduce the risk of stroke in patients in
sinus rhythm. However, in the largest of these, the Warfarin vs.
Aspirin in Reduced Cardiac Ejection Fraction trial (WARCEF),
although warfarin was effective in reducing ischaemic stroke this bene-
fit was offset by major bleeding. With non-vitamin K oral anticoagu-
lants, the risk-to-benefit balance might be more favourable, especially
as the target International Normalized Ratio (INR) in WARCEF was
2.75 (range 2.0–3.5).34–37
Limitations
Each of the two trials included had specific inclusion and exclusion
criteria and, hence, our findings may not be generalizable to all
patients with HF-PEF. Notably, few patients were in NYHA class IV
and worse functional class was a predictor of higher risk of stroke.
Hence, the risk of stroke may be higher in ‘real world’ patients than in
the cohort studied. Although our data suggest that only the minority
of strokes is related to incident AF, systematic detection of new
onset AF was insensitive, e.g. continuous ambulatory monitoring was
Figure 3 Distribution of risk score for stroke and its relation to
predicted risk of stroke within the follow-up period.
Figure 4 Kaplan–Meier plot for stroke according to tertile of risk
score in patients without atrial fibrillation.
Figure 5 Comparison of observed and expected stroke rates
after 3 years for patients categorized by tertile of risk-score derived
from the heart failure with reduced ejection fraction stroke model.7
Observed shows the 3 year Kaplan–Meier rate for each tertile;
expected shows estimate from the Cox model for each tertile.
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not performed. It is widely recognized that silent AF is frequent in
heart failure and undetected AF may have accounted for more
strokes than realized. However, waiting for the development of clini-
cally recognized AF before employing anticoagulant therapy may not
be the ideal preventive strategy and the best and most cost-effective
way to screen for silent AF in HF-PEF is unknown. In addition, these
patients may have other reasons to develop thromboembolic and
other types of ischaemic stroke, e.g. endothelial dysfunction and
blood stasis. Therefore, we believe that our findings support a poten-
tial preventive role for anticoagulant therapy in HF-PEF patients in
sinus rhythm, particularly as new agents with a lower risk of bleeding
are available. Of course, this hypothesis needs to be tested prospec-
tively in a randomized trial and it may be too simplistic to assume that
an anticoagulant can substantially reduce the risk of stroke in those
with HF-PEF at highest risk.
CHARM-Preserved and I-Preserve were randomized controlled
heart failure trials, rather than stroke trials, and used definitions of
stroke consistent with other heart failure trials conducted during the
same period. Although the definition may not be identical to that
used in contemporary stroke trials, it was applied consistently by
adjudicators blind to treatment allocation and thus gave an unbiased
estimate of treatment effect. Unfortunately, classification of stroke
subtype was not carried out in both trials. When the trials were con-
ducted, neuroimaging was not standard in patients with suspected
stroke in many, if not most countries, involved. Therefore, we are
unable to distinguish between ischaemic and haemorrhagic strokes.
In conclusion, we found that a relatively high-risk subset of a third
of HF-PEF patients without AF have a risk of stroke similar to that in
HF-PEF patients with AF. This higher-risk subset can be identified
using five simple clinical variables. The risk of stroke is similar in HF-
PEF and HF-REF patients without AF and is predicted by the same
variables. The risk of stroke in these patients might be reduced by
treatment with an oral anticoagulant but this hypothesis needs to be
tested in a clinical trial. The rate of stroke in the highest risk tertile
was not quite as high as in patients with AF not treated with an anti-
coagulant so it is uncertain what the benefit/risk ratio of such treat-
ment might be.
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